Aurinia Announces 2024 Annual General Meeting Results
June 14 2024 - 12:16PM
Business Wire
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the
Company) today announced voting results for its 2024 annual general
meeting (the Meeting) of shareholders held on June 14, 2024.
Shareholders re-elected five of nine incumbent directors to the
Board of Directors (the Board). The four directors, while elected
under applicable corporate law, who received less than majority
support are Peter Greenleaf, Director, President and CEO; Daniel G.
Billen, Ph.D., Director, Chair of the Board, Chair of the
Compensation Committee, and Member of the Audit Committee; R.
Hector MacKay-Dunn, J.D., K.C., Director, Chair of the Governance
& Nomination Committee and Member of the Compensation
Committee; and Brinda Balakrishnan, M.D., Ph.D., Director, Member
of the Compensation Committee.
As required by the Company’s Majority Voting Policy, these
directors have submitted their conditional resignations as
directors of the Company for consideration by the Board. Pursuant
to the Majority Voting Policy, the Board will consider these
conditional resignations and communicate their decision and
resulting actions within the 90-day period specified in the
Majority Voting Policy.
In addition, the Company’s re-appointment of
PricewaterhouseCoopers, LLP, as its independent registered public
accounting firm received majority support, while the non-binding
advisory vote on executive compensation did not receive majority
support. In addition, the proposed amendment to the equity
incentive plan was not approved at the Meeting. Accordingly, the
existing equity incentive plan continues unaffected, without
amendment.
“We respect the opinions of all our shareholders and welcome a
continued dialogue with them. We understand that there is
considerable work to be completed in the coming months. We are
focused on moving forward with the goal of increasing shareholder
value and delivering LUPKYNIS to people living with lupus
nephritis,” said Dr. Daniel Billen, Chairman of the Board of
Aurinia.
A report of voting results on all matters voted on at the
Meeting will be filed on SEDAR at www.sedarplus.ca and EDGAR at
www.sec.gov/edgar.
About Aurinia
Aurinia Pharmaceuticals is a fully integrated biopharmaceutical
company focused on delivering therapies to people living with
autoimmune diseases with high unmet medical needs. In January 2021,
the Company introduced LUPKYNIS® (voclosporin), the first
FDA-approved oral therapy dedicated to the treatment of adult
patients with active lupus nephritis. The Company’s head office is
in Edmonton, Alberta, with its U.S. commercial office in Rockville,
Maryland. The Company focuses its development efforts globally.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240614491391/en/
Media and Investor Inquiries: Andrea Christopher
Corporate Communications and Investor Relations, Aurinia
achristopher@auriniapharma.com ir@auriniapharma.com
Aurinia Pharmaceuticals (NASDAQ:AUPH)
Historical Stock Chart
From Jul 2024 to Aug 2024
Aurinia Pharmaceuticals (NASDAQ:AUPH)
Historical Stock Chart
From Aug 2023 to Aug 2024